Syndax Pharmaceuticals Announces Transition of Michael A. Metzger to Chief Executive Officer; Briggs W. Morrison, M.D., to Assume Role of President, Head of Research & Development

/PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an...

Related Keywords

David Rosen ,Briggsw Morrison ,Regado Biosciences ,Melissa Forst ,Michaela Metzger ,Global Medicines Development ,Head Of Research ,Linkedin ,Company On Twitter ,Syndax Pharmaceuticals ,Merck Co ,Nasdaq ,University Of Connecticut ,York University Stern School Of Business ,Astrazeneca ,George Washington University ,Georgetown University ,Allergan ,Morrison ,Regulatory Affairs At Pfizer ,Company Board Of Directors ,Clinical Sciences ,Exchange Commission ,Prnewswire Syndax Pharmaceuticals Inc ,Syndax Pharmaceuticals Inc ,Chief Operating Officer ,Chief Executive Officer ,New Drug Application ,Tobira Therapeutics ,Mersana Therapeutics ,Forest Laboratories ,New York University Stern School ,Executive Vice President ,Chief Medical Officer ,Medical Affairs ,Regulatory Affairs ,Vice President ,Private Securities Litigation Reform Act ,Nc ,